Peptide corresponding to the C terminus of tissue factor pathway inhibitor inhibits mesangial cell proliferation and activation in vivo.

Wang Liang,Juan Cheng,Rui Liu,Ji-ping Wang,Jin-gui Mu,Qing-hua Wang,Hui-jun Wang,Duan Ma
DOI: https://doi.org/10.1016/j.peptides.2009.08.016
IF: 3.867
2009-01-01
Peptides
Abstract:Mesangial cells (MsCs) are one of the resident cell types in the glomerulus and are important with respect to its function and structure. The activation and proliferation of MsCs occur in several types of glomerulonephritis, particularly proliferative glomerulonephritis, producing a series of protein factors and matrix components that impair the normal structure and function of the glomerulus. To inhibit proliferation or induction of apoptosis is considered to be one mechanism that can be used to treat these diseases. In previous studies, we found that the tissue factor pathway inhibitor (TFPI) induces the apoptosis of cultured rat MsCs. Here, we expressed a series of TFPI fragments as fusion proteins to maltose binding protein (MBP-TFPI162–188, MBP-TFPI187–241, MBP-TFPI240–276, MBP-TFPI162–241, MBP-TFPI187–276 and MBP-TFPI162–276) and applied them to cultured rat mesangial cells. The C terminus of TFPI, a peptide corresponding to residues 240–276 of TFPI, was confirmed to induce apoptosis of MsCs in vitro. To observe the effect of this peptide on MsCs in vivo, we performed intramuscular gene transfer treatment on a rat model of proliferative glomerulonephritis with a plasmid containing the gene for the C terminus of TFPI. This revealed that the C terminus of TFPI exhibited suppressive effects on the activation and proliferation of MsCs and, thereby, improved renal function. Our data indicate that the C terminus of TFPI could be used in the treatment of proliferative glomerulonephritis.
What problem does this paper attempt to address?